Abstract
Breast chondrosarcoma is a rare sarcoma that mainly occurs in females >50 years old. To the best of our knowledge, only 16 cases were reported in the literature prior to 2013 and all patients were surgically treated by mastectomy, with or without lymphadenectomy, which was occasionally preceded by neoadjuvant chemotherapy. However, the literature does not report the benefit of mastectomy compared with a more conservative surgery. The present study reports a novel case of extraskeletal chondrosarcoma of the breast. A 63-year-old female patient presented with a neoplasm localized in the upper-outer quadrant of the right breast. The palpable lesion with sharp margins was a firm parenchymatous mass, which was confirmed by ultrasonography and mammography. The patient underwent conservative quadrantectomy instead of mastectomy, followed by post-surgical chemotherapy. A positron emission tomography scan performed five months subsequent to the surgery revealed no remnants of the disease. The patient underwent a strict clinical and instrumental follow-up, and two and half years after surgery, there are no signs of recurrent disease. In conclusion, the present case is currently one of the two cases in which a more conservative quadrantectomy was performed, instead of mastectomy. This surgical approach did not lead to metastasis and resulted in a good follow-up for the patient.
Keywords: chondrosarcoma, sarcoma, breast, surgery, mastectomy
Introduction
Sarcomas are tumors that rarely occur in the breast, accounting for 0.5–1% of all breast cancers (1). Sarcomas arise from the stromal tissue of the mammary gland and if angiosarcoma, which has a more severe prognosis, is excluded, the course of the disease is not significantly different compared with tumors arising from other sites (2). Chondrosarcoma is a rare type of sarcoma that, to the best of our knowledge, was reported in only five cases in the literature prior to 2001 (3–6) and 11 cases in the literature between 2002 and 2013 (7–17), and mainly occurs in females >50 years old. Macroscopically, chondrosarcoma appears as a whitish-gray, round mass with regular margins and necrotic, hemorrhagic or cystic areas that is characterized by rapid growth, although the sarcoma rarely invades locally or metastasizes to lymph nodes (9–13,18,19). Chondrosarcoma is microscopically characterized by chondroid lacunae, in which numerous chondroblasts exhibit hyperchromatic nuclei and the absence of epithelial areas or other stromal components, with a high mitotic division rate. There is also an absence of estrogen, androgen or HER2 receptors, with a strong expression of the S100 protein, cytokeratin and the membrane epithelial antigen (1). Ultrasonography reveals a hyperechogenic formation, with a polylobated shape, while mammography exhibits a round hyperdense mass with regular margins, which may simulate a benign lesion (20). The differential diagnosis of chondrosarcoma is usually between malignant phyllodes tumor (PT), metaplastic carcinoma (MC), in which a significant percentage of metaplastic elements (>10%) are present, and matrix-producing metaplastic carcinoma (MP-MC), a rare cancer of the breast characterized by osteoid and chondral matrices and the presence of carcinomatous features (20,21). The mainstay of treatment for sarcoma of the breast, as with sarcomas at other sites, is a surgical procedure combined with mastectomy (20). The present study describes a novel case of extraskeletal chondrosarcoma of the breast that was treated with a more conservative surgical treatment instead of mastectomy, as an innovative surgical approach. Written informed consent was obtained from the patient.
Case report
A 63-year-old female presented to Umberto I Hospital, Sapienza University (Rome, Italy) with a neoplasm localized in the upper-outer quadrant of the right breast (RUO). The palpable lesion was a firm parenchymatous mass that was mobile on the superficial and deep planes, exhibited sharp margins and a poor homogeneous surface and was not painful. There was no evident axillary lymphadenopathy. An X-ray mammogram revealed the enhancement of a previously observed opacity in the superolateral quadrant, with partial sharp margins. Using core biopsy, the mass was determined to be a mammary parenchyma in continuity with hypercellular condroid tissue, with the presence of atypical, occasionally polynuclear elements, and rare mitosis. Ultrasonography revealed the presence of a hypoechoic, solid neoformation with jagged edges and a maximum diameter of ~3 cm (Fig. 1). Mammography revealed an upper-outer para-areolar oval opacity with partially shaded contours that demonstrated the presence of an adequate margin of healthy perilesional tissue (Fig. 2). The formation was delimited and split by fibrous stroma, in which ductal structures and ectatic vessels were present. The tumor appeared to be a malignant mesenchymal neoplasm with chondroid differentiation, although it could not be excluded that the formation was a component of a biphasic lesion similar to phyllodes tumors. Considering the size of the lesion, the overall dimensions of the breast and the lack of literature reporting a genuine benefit of mastectomy compared with more conservative surgery (Table I), it was decided to refer the patient for a wide RUO quadrantectomy, to include any skip metastasis. For an improved examination, tissue samples of the resection margins were separately analyzed by a pathologist.
Table I.
First author, year (reference) | Gender | Age, years | Tumor site, breast | Method used for diagnosis | Therapy | Follow-up |
---|---|---|---|---|---|---|
Errarhay et al, 2013 (7) | Female | 24 | Right | Mammography and tumorectomy | Mastectomy | NR |
Mujtaba et al, 2013 (13) | Female | 40 | Right | Mammography and CT | Mastectomy | |
Badyal et al, 2012 (8) | Male | 80 | Right | FNAC | Mastectomy and axillary lymphadenectomy | Yes |
Patterson et al, 2011 (12) | Female | 52 | Left | FNAC and core biopsy | Mastectomy and RT | Yes |
Lakshmikant et al, 2010 (14) | Female | 42 | Left | Core biopsy | Mastectomy | NR |
Bhosale et al, 2010 (15) | Female | 45 | Right | Tumorectomy and axillary lymph node FNAC | Mastectomy and axillary lymphadenectomy, RT-CHT | Yes |
De Padua et al, 2009 (11) | Female | 56 | Right | FNAC | Mastectomy and RT | NR |
Gurleyik et al, 2009 (16) | Female | 52 | Right | Ultrasonography, mammography, FNAC and tumorectomy | Mastectomy and axillary lymphadenectomy | NR |
Gupta et al, 2006 (10) | Female | 46 | Left | FNAC | Mastectomy | NR |
Verfaille et al, 2005 (17) | Female | 77 | Right | Ultrasonography, mammography and Tru-cut needle biopsy | Mastectomy | NR |
Gupta et al, 2003 (9) | Female | 46 | Left | FNAC | Mastectomy, neoadjuvant CHT, RT and lymphadenectomy | NR |
CT, computed tomography; FNAC, fine-needle aspiration cytology; RT, radiotherapy; CHT, chemotherapy; NR, not reported.
Histopathological results
The gross post-surgical examination revealed a mammary-parenchymal section, 6.5×4.5×5 cm in size, covered by 4.1 cm of skin. Following the cut, a round-shaped neoplasm was observed, possessing a maximum diameter of 3 cm and exhibiting gelatinous and tense-elastic regions. The biopsy specimen from the neoplasm revealed the proliferation of mesenchymal cells with round nuclei, eosinophilic cytoplasm and ill-defined boundaries. The neoplastic elements were arranged in groups of varying sizes, in the context of a layer with a basophilic myxoid appearance. A chondroid-type layer was present at the periphery of the lesion, with a star-shaped appearance and pleomorphic nuclei. Certain figures were suggestive of invasion, however, no perilesional venous vessel invasion was detected. The mitotic index was seven out of 10 fields of high magnification. The tumor possessed large areas of necrosis. The neoplastic elements exhibited 50% of the proliferation index, as evaluated by Ki-67 staining. The remaining parenchyma demonstrated a nodular lesion with a diameter of 1.2 cm attributable to stromal fibrosis, in the absence of further significant atypia. All resection margins were separately analyzed by a pathologist and were found to be free from cancer-associated elements. A diagnosis of chondrosarcoma of the breast was finally made.
Post-surgical treatments
Subsequent to surgery there was a discussion between the various consulted oncologists on the necessity of further treatments, as the role of chemotherapy and radiotherapy in primary breast chondrosarcoma is unresolved (1). Despite the possibility that adjuvant therapy may decrease the rates of local and systematic recurrence, the literature is lacking in significant information regarding the benefit of post-surgery chemo- or radiotherapy in the face of the side-effects of those therapies, due to the rarity of this disease and the small number of cases reported (1). It was decided, with the consent of the patient, to administer five cycles of standard radiotherapy on the residual breast tissue (50 Gy) and operative site (10 Gy), used only as a complement to radical surgery, and six cycles of precautionary chemotherapy for six weeks, with epirubicin (120 mg per cycle) and ifosfamide (2,950 mg per cycle), as previously reported (1). A positron emission tomography scan performed five months after the surgery excluded the presence of remnants of the disease (Fig. 3). Therefore, whilst the patient continues to undergo a strict clinical and instrumental follow-up two and half years after surgery, there are no signs of recurrent disease.
Discussion
The present study describes a novel case of extraskeletal chondrosarcoma of the breast that was treated with a more conservative quadrantectomy instead of mastectomy, as an innovative surgical approach. The benefit of performing quadrantectomy instead of mastectomy is not addressed in the literature (1,2). Between 1967 and 2001, only five cases of chondrosarcoma of the breast were reported in the literature, and all were treated with mastectomy (3–6). The present review revealed that between 2001 and 2013 only 11 other cases were described, as summarized in Table I. All the 16 studies, consisting of 15 female patients and one male patient, reported mastectomy as the surgical treatment choice. In four cases mastectomy was associated with lymphadenectomy and in one case mastectomy was preceded by neoadjuvant chemotherapy (Table I). The choice of mastectomy was dictated not only by a strictly local situation of the lesion, but also by the lack of previous studies, due to the rarity of the lesion, and by an old interpretation of the surgical approach to sarcoma at this particular site.
Although surgery remains the gold standard for the treatment of breast sarcoma, and chondrosarcoma in particular (1), there is no uniformity of view on the most effective type of surgery that may justify the requirement for radical intervention, such as mastectomy, compared to surgery with wide tumor-free margins (20). According to a study performed by Zelek et al (22), and another previous study (23), mastectomy for sarcomatous malignancy should not be associated with axillary lymphadenectomy, as the sarcoma does not exhibit a tendency to spread through lymphatic system, but mainly through the haematogenous route. Furthermore, the lymphectomy exposes the patient to greater morbidity without a real benefit in terms of disease-free and overall survival (20). Thus, lymphectomy should be indicated only if the lesion is associated with an epithelial component or when all breast quadrants are involved, in particular the upper-outer (superolateral) quadrants (20).
In previous years, the surgical approach to all sarcomas, and in particular to those of the breast, has been reevaluated as it has been found that an extensive surgical procedure may be considered adequate, providing that the curative wide margins of healthy peritumoral tissue are sufficiently respected, to ensure that the margins include any skip metastasis with the excision (2,24,25). At present, only two factors have been demonstrated to affect the outcome of surgery, the extent of the tumor and the margins of excision. Tumors >5 cm in size result in a poorer prognosis compared with those of smaller dimensions (20). In addition, the majority of authors agree that a resection margin of 1 cm is sufficient for small and localized sarcomas, and this approach is compatible with a conservative surgery. Therefore, in the present study, it was decided to treat the chondrosarcoma of the breast with surgery, in consideration of the size of the lesion, and, in particular, to use a more conservative quadrantectomy instead of mastectomy, as a novel surgical approach. This approach was chosen with the consideration that a greater efficacy has not been proven or demonstrated in patients treated with mastectomy in terms of overall and disease-free survival compared with patients treated by adequate quadrantectomy.
The present treatment strategy was in agreement with a previous retrospective study revealing that, for sarcomas of the breast, the radical treatment of mastectomy did not offer significant survival benefits compared with the wide excision option of quadrantectomy (20). By contrast, the study revealed a more severe prognosis for the patients that underwent simple lumpectomy. Notably, at the time of writing, a novel case report was published in the literature that used a similar conservative breast surgery approach (26), supporting the present approach of performing quadrantectomy instead of mastectomy.
Acknowledgements
The authors would like to thank the patient who participated in this study.
References
- 1.Lewin J, Puri A, Quek R, Ngan R, Alcasabas AP, Wood D, Thomas D. Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. Lancet Oncol. 2013;14:e562–e570. doi: 10.1016/S1470-2045(13)70475-3. [DOI] [PubMed] [Google Scholar]
- 2.Demetri GD, Antonia S, Benjamin RS, et al. National Comprehensive Cancer Network Soft Tissue Sarcoma Panel: Soft tissue sarcoma. J Natl Compr Canc Netw. 2010;8:630–674. doi: 10.6004/jnccn.2010.0049. [DOI] [PubMed] [Google Scholar]
- 3.Kennedy T, Biggart JD. Sarcoma of the breast. Br J Cancer. 1967;21:635–644. doi: 10.1038/bjc.1967.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Beltaos E, Banerjee TK. Chondrosarcoma of the breast: Report of two cases. Am J Clin Pathol. 1979;71:345–349. doi: 10.1093/ajcp/71.3.345. [DOI] [PubMed] [Google Scholar]
- 5.Thilagavathi G, Subramanian S, Samuel AV, Rani U, Somasundaram C. Primary chondrosarcoma of the breast. J Indian Med Assoc. 1992;90:16–17. [PubMed] [Google Scholar]
- 6.Guymar S, Ferlicot S, Genestie C, Gelberg JJ, Blondon J, Le Charpentier Y, Zafrani B. Breast chondrosarcoma: a case report and review. Ann Pathol. 2001;21:168–171. (In French) [PubMed] [Google Scholar]
- 7.Errarhay S, Fetohi M, Mahmoud S, et al. Primary chondrosarcoma of the breast: a case presentation and review of the literature. World J Surg. 2013;11:208. doi: 10.1186/1477-7819-11-208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Badyal RK, Kataria AS, Kaur M. Primary chondrosarcoma of male breast: a rare case. Indian J Surg. 2012;74:418–419. doi: 10.1007/s12262-012-0439-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gupta S, Gupta V, Aggarwal PN, Kant R, Khurana N, Mandal AK. Primary chondrosarcoma of the breast: a case report. Indian J Cancer. 2003;40:77–79. [PubMed] [Google Scholar]
- 10.Gupta S, Gupta V, Aggarwal PN, Kant R, Dass PM, Khurana N, Mandal AK. Primary chondrosarcoma of the breast. J Indian Med Assoc. 2006;104:99–100. [PubMed] [Google Scholar]
- 11.De Padua M, Bhandari TP. Primary mesenchymal chondrosarcoma of the breast. Indian J Pathol Microbiol. 2009;52:129–130. doi: 10.4103/0377-4929.44979. [DOI] [PubMed] [Google Scholar]
- 12.Patterson JD, Wilson JE, Dim D, Talboy GE. Primary chondrosarcoma of the breast: report of a case and review of the literature. Breast Dis. 2011;33:189–191. doi: 10.3233/BD-2009-0303. [DOI] [PubMed] [Google Scholar]
- 13.Mujtaba SS, Haroon S, Faridi N. Primary chondrosarcoma of breast. J Coll Physicians Surg Pak. 2013;23:754–755. doi: 10.2013/JCPSP.754755. [DOI] [PubMed] [Google Scholar]
- 14.Lakshmikantha A, Kawatra V, Varma D, Khurana N. Primary breast chondrosarcoma. Breast J. 2010;16:553–554. doi: 10.1111/j.1524-4741.2010.00960.x. [DOI] [PubMed] [Google Scholar]
- 15.Bhosale SJ, Kshirsagar AY, Sulhyan SR, et al. Metaplastic carcinoma with predominant chondrosarcoma of the right breast. Case Rep Oncol. 2010;3:277–281. doi: 10.1159/000319423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Gurleyik E, Yildirim U, Gunai O, Pehlivan M. Malignant mesenchymal tumor of the breast: primary chondrosarcoma. Breast Care (Basel) 2009;4:101–103. doi: 10.1159/000212101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Verfaillie G, Breucq C, Perdaens C, et al. Chondrosarcoma of the breast. Breast J. 2005;11:147–148. doi: 10.1111/j.1075-122X.2005.21573.x. [DOI] [PubMed] [Google Scholar]
- 18.Rao L, Kudva R, Rao RV, Kumar B. Extraskeletal myxoid chondrosarcoma of the chest wall masquerading as a breast tumor. A case report. Acta Cytol. 2002;46:417–421. doi: 10.1159/000326743. [DOI] [PubMed] [Google Scholar]
- 19.Vera-Sempere F, García-Martínez A. Malignant phyllodes tumor of the breast with predominant chondrosarcomatous differentiation. Pathol Res Pract. 2003;199:841–845. doi: 10.1078/0344-0338-00505. [DOI] [PubMed] [Google Scholar]
- 20.Pencavel TD, Hayes A. Breast sarcoma - a review of diagnosis and management. Int J Surg. 2009;7:20–23. doi: 10.1016/j.ijsu.2008.12.005. [DOI] [PubMed] [Google Scholar]
- 21.Rakha EA, Tan PH, Shaaban A, et al. Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast. 2013;22:13–18. doi: 10.1016/j.breast.2012.09.010. [DOI] [PubMed] [Google Scholar]
- 22.Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol. 2003;21:2583–2588. doi: 10.1200/JCO.2003.06.080. [DOI] [PubMed] [Google Scholar]
- 23.Pasta V, Monti M, Antonucci D, Di Matteo FM, Boccaccini F, Brescia A. Primary sarcoma of the breast: criteria for radical surgery. G Chir. 1997;18:703–706. (In Italian) [PubMed] [Google Scholar]
- 24.Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CD, Singer S. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999;17:3252–3259. doi: 10.1200/JCO.1999.17.10.3252. [DOI] [PubMed] [Google Scholar]
- 25.Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424–434. doi: 10.1097/00000658-200203000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Faraht A, Magdy N, Elaffandi A. Primary myxoid chondrosarcoma of the breast. Ann R Coll Surg Engl. 2014;96:112E–411E. doi: 10.1308/003588414X13824511649210. [DOI] [PMC free article] [PubMed] [Google Scholar]